Medtronic receives FDA warning
This article was originally published in Clinica
Medtronic has been issued with a warning from the FDA relating to quality issues at a Minneapolis, Minnesota plant that manufactures implantable drug infusion and neurostimulation products. In a letter dated July 3, the FDA told Medtronic that inspections of the plant revealed several violations of federal regulations, including: misbranding of devices: an inadequate complaint handling procedure; and failure to report malfunctions with its implantable SynchroMed pump, including catheter separation or fracture, and inflammatory masses and granulomas, all of which could lead to serious injury.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.